A multicenter, randomized, double blind, placebo-controlled clinical trial of DL-3-n-butylphthalide in treatment of amyotrophic lateral sclerosis.
10.1097/CM9.0000000000002442
- Author:
Mingsheng LIU
1
;
Xiaoli YAO
2
;
Xusheng HUANG
3
;
Huifang SHANG
4
;
Dongsheng FAN
5
;
Jia HE
6
;
Liying CUI
1
Author Information
1. Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
2. Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.
3. Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China.
4. Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
5. Department of Neurology, Peking University Third Hospital, Beijing 100191, China.
6. Department of Health Statistics, Faculty of Health Service, Naval Medical University, Shanghai 200433, China.
- Collective Name:Chinese ALS Study Group
- Publication Type:Letter
- MeSH:
Humans;
Amyotrophic Lateral Sclerosis/drug therapy*;
Benzofurans/therapeutic use*;
Double-Blind Method;
Treatment Outcome
- From:
Chinese Medical Journal
2023;136(3):354-356
- CountryChina
- Language:English
